Experimental drug telaglenastat aims to lower lung blood pressure

NCT ID NCT07223528

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether the drug telaglenastat, taken twice daily for 12 weeks, can safely lower blood pressure in the lungs and improve heart and lung function in adults with pulmonary hypertension. About 28 participants will receive the drug on top of their usual care. The main measure is a change in lung blood vessel resistance, assessed by a heart catheterization.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Telaglenastat (CB-839), a drug taken by mouth twice daily
What this could lead to
If it works, this could point toward a new treatment option for pulmonary hypertension that improves blood flow in the lungs and heart function.
What could go wrong
This is a small, early-phase trial with only 28 people and no placebo group, so results may not apply widely. The drug is not FDA-approved for this condition and may not work or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PULMONARY HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • UPMC Presybeterian

    Pittsburgh, Pennsylvania, 15213, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.